Development
ImmunoPrecise Antibodies Ltd.
IPA
$0.6724
-$0.0296-4.22%
NASDAQ
| 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -11.88M | -15.47M | -20.09M | -19.97M | -19.50M |
| Total Depreciation and Amortization | 4.17M | 4.29M | 4.50M | 2.82M | 2.53M |
| Total Amortization of Deferred Charges | 658.30K | 642.10K | 525.20K | 1.47M | 1.26M |
| Total Other Non-Cash Items | 2.69M | 2.64M | 2.47M | 480.60K | 1.23M |
| Change in Net Operating Assets | -616.70K | 280.40K | -2.51M | 331.50K | -1.82M |
| Cash from Operations | -4.98M | -7.62M | -15.11M | -14.87M | -16.31M |
| Capital Expenditure | -845.00K | -1.15M | -1.12M | -888.30K | -1.08M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -96.10K | -554.50K | -445.10K | -3.37M | -3.37M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 68.20K | 153.70K | 90.00K | -114.40K | -279.30K |
| Cash from Investing | -873.00K | -1.55M | -1.47M | -4.38M | -4.73M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.48M | -1.47M | -1.34M | -1.22M | -1.07M |
| Issuance of Common Stock | 98.00K | 597.00K | 716.00K | 4.04M | 4.13M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -5.00K | -5.00K |
| Cash from Financing | -1.02M | -648.30K | -462.80K | 2.24M | 2.40M |
| Foreign Exchange rate Adjustments | 168.50K | 491.60K | 547.70K | 376.40K | 536.70K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.70M | -9.32M | -16.49M | -16.63M | -18.10M |